SG11202001709WA - Tlr-9 agonists for modulation of tumor microenvironment - Google Patents

Tlr-9 agonists for modulation of tumor microenvironment

Info

Publication number
SG11202001709WA
SG11202001709WA SG11202001709WA SG11202001709WA SG11202001709WA SG 11202001709W A SG11202001709W A SG 11202001709WA SG 11202001709W A SG11202001709W A SG 11202001709WA SG 11202001709W A SG11202001709W A SG 11202001709WA SG 11202001709W A SG11202001709W A SG 11202001709WA
Authority
SG
Singapore
Prior art keywords
tlr
agonists
modulation
tumor microenvironment
microenvironment
Prior art date
Application number
SG11202001709WA
Inventor
Kerstin Kapp
Manuel Schmidt
Original Assignee
Mologen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen Ag filed Critical Mologen Ag
Publication of SG11202001709WA publication Critical patent/SG11202001709WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
SG11202001709WA 2017-08-31 2018-08-31 Tlr-9 agonists for modulation of tumor microenvironment SG11202001709WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17001465 2017-08-31
EP18151734 2018-01-15
PCT/EP2018/073536 WO2019043194A1 (en) 2017-08-31 2018-08-31 Tlr-9 agonists for modulation of tumor microenvironment

Publications (1)

Publication Number Publication Date
SG11202001709WA true SG11202001709WA (en) 2020-03-30

Family

ID=63557427

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202001683SA SG11202001683SA (en) 2017-08-31 2018-08-31 Tlr-9 agonists for modulation of tumor microenvironment
SG11202001709WA SG11202001709WA (en) 2017-08-31 2018-08-31 Tlr-9 agonists for modulation of tumor microenvironment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202001683SA SG11202001683SA (en) 2017-08-31 2018-08-31 Tlr-9 agonists for modulation of tumor microenvironment

Country Status (7)

Country Link
US (2) US20210079403A1 (en)
EP (2) EP3691749A1 (en)
JP (2) JP2020531554A (en)
CN (2) CN111278509A (en)
SG (2) SG11202001683SA (en)
TW (1) TW201919652A (en)
WO (2) WO2019043192A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN113747580A (en) 2020-05-28 2021-12-03 华为技术有限公司 Communication method and device
EP4104830A1 (en) * 2021-06-16 2022-12-21 Burghardt Wittig Sequential innate and adaptive immune modulation for cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19935756A1 (en) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Covalently closed nucleic acid molecule for immune stimulation
JP2009511034A (en) * 2005-10-12 2009-03-19 キャンサー・リサーチ・テクノロジー・リミテッド Methods and compositions for treating immune disorders
ES2357692T3 (en) * 2006-05-11 2011-04-28 Mologen Ag MULTIMERO FOR IMMUNOSTIMULATION.
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
GB2523187A (en) 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
LU92821B1 (en) * 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides

Also Published As

Publication number Publication date
JP2020531554A (en) 2020-11-05
CN111278509A (en) 2020-06-12
CN111278510A (en) 2020-06-12
WO2019043194A1 (en) 2019-03-07
TW201919652A (en) 2019-06-01
SG11202001683SA (en) 2020-03-30
EP3684470A1 (en) 2020-07-29
US20210155933A1 (en) 2021-05-27
US20210079403A1 (en) 2021-03-18
WO2019043192A1 (en) 2019-03-07
JP2020531555A (en) 2020-11-05
EP3691749A1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
SG11202001709WA (en) Tlr-9 agonists for modulation of tumor microenvironment
IL271149A (en) Compounds for modulating s1p1 activity and methods of using the same
IL264674B1 (en) Anti-siglec-7 antibodies for the treatment of cancer
IL245016A0 (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
IL265370B (en) Immune modulation with tlr9 agonists for cancer treatment
IL264216A (en) Compounds and methods for modulation of smn2
HK1254289A1 (en) Methods and antibodies for modulation of immunoresponse
HRP20181672T1 (en) Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
IL258378B (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
PT3609497T (en) Combination therapy for prostate cancer
HK1257177A1 (en) Tumor immunotherapy
ZA201904736B (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy
IL247818B (en) Methods for improving cognitive function via modulation of quinone reductase 2
IL261089A (en) Methods of immunogenic modulation
IL256055B (en) Use of h3k9me3 modulation for enhancing cognitive function
GB201709747D0 (en) Localization of mobile devices
ZA201606921B (en) Use of xanthophylls for the treatment of cancers
PT3682889T (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
EP3438130A4 (en) Anti-podocalyxin antibody that targets tumor microenvironment
PL3630754T3 (en) Isoindoline-acetylene compounds for the treatment of cancer
GB2558296B (en) Radio frequency modulator
PT3551901T (en) Disc carrier
ZA201707117B (en) Antibody compositions for tumor treatment
GB201717004D0 (en) Methods of cancer therapy
PT3377106T (en) Modulation of ciliogenesis